Curcumin is documented for use in gastrointestinal problems (through downregulation of NF-kB, IL-6, TRPV-1, and STAT3) (Rajasekaran, 2011; Lopresti, 2018), liver diseases (inhibition of TGF-β) (Espinoza and Muriel, 2009), inflammatory conditions (suppression of TNF-α, IL-6, 8, and 12, COX-2, and iNOS) (Fadus et al., 2017; Hewlings and Kalman, 2017), and as an anticancer drug (repressing IL-10 and 18, AP-1, Pgp {Akt/IKKα- β/NF-kB axis} and activation of MAPK) (Liu and Ho, 2018; Tomeh et al., 2019). The gene discussed is NFKB1; the disease is liver disorder.